Thrombophilia and pregnancy

Hematology

Volumn 10, Issue SUPPL. 1, 2005, Pages 186-189

  Brenner, B ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Factor V; Heparin; Pregnancy; Thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; APC; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN;

BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FETUS WASTAGE; GENE MUTATION; GENOTYPE; GESTATION PERIOD; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOPHILIA; THROMBOSIS; VAGINAL DELIVERY; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM;

ABORTION, HABITUAL; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 29244466452     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330512331390366     Document Type: Review

References (32)

1. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982;14:127-141.
2. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S. Thromb Haemost 1990;63:319-320.
3. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000;342:374-379.
4. Triplett DA, Harris EN. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 1989;21:123-131.
5. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland WC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 1995;155:1217-1222.
6. Sanson BJ, Friederich PW, Simioni P, et al. The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women. Thromb Haemost 1996;75:387-388.
7. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151-161.
8. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-824.
9. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N. Thrombophilic polymorphisms in women with fetal loss. Thromb Haemost 1999;82:6-9.
10. Dizon-Townson DS, Kinney S, Branch DW, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997;34:217-223.
11. Meinardi JR, Middeldorp S, de Kam PJ, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-739.
12. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624-1627.
13. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551-554.
14. Clark P, Brennand J, Conkie JA, McCall D, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-1170.
15. Kjelberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999;81:527-531.
16. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haemotol 1996;92:489-490.
17. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000;43:31-35.
18. Mandel H, Brenner B, Berant M, et al. Coexistence of hereditary homocysteinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996;334:763-768.
19. Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden - impact on thrombotic diathesis. Br J Haematol 1996;94:166-167.
20. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916.
21. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood 2004;103:4003-4009. Review.
22. Infante-Rivard C, Rivard GE, Guiguet M, Gauthier R. Thrombophilic polymorphism and intrauterine growth restriction. Epidemiology 2005;16:281-287.
23. Kupferminc MJ, Rimon E, Ascher-Landsberg J, lessing JB, Many A. Perinatal outcome in women with severe pregnancy complications and multiple thrombophilias. J perinat Med 2004;32:225-227.
24. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late foetal-loss and no thrombotic antecedent-the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost 1999;81:891-899.
25. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilias in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
26. Grandone E, Margaglione M, Colaizzo D, et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998;179:1324-1328.
27. Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, et al. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost 1999;81:668-672.
28. Gris JC, Neveu S, Tailland ML, Courtieu C, Mares P, Schved JF. Use of low-molecular weight heparin (Enoxaparin) or of a phenformin-like substance (Moroxydine Chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thromb Haemost 1995;73:362-367.
29. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 2000;83:693-697.
30. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J, et al. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the LIVE-ENOX study. JTH 2005;3:227-229.
31. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Neveu S, Tailland ML, Dauzat M, Mares P. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 3695-3699.
32. Dizon-Townson DS, Meline L, Nelson LM, Varner M, Ward K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol 1997;177:402-405.